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ABSTRACT
Transfection of DNA has been invaluable for biological sciences, yet the effects upon membrane homeostasis are far from negligible. Here, we
demonstrate that Neuro2A cells transfected using Lipofectamine LTXwith the ﬂuorescently coupled Botulinum serotype A holoenzyme (EGFP-
LcA)cDNAexpress thisSNAP25protease that can,once translated, escape the transfectedhost cytosolandbecomeendocytosed intountransfected
cells, without its innate binding and translocation domains. Fluorescent readouts revealed moderate transfection rates (30–50%) while
immunoblotting revealed a surprisingly total enzymatic cleavage of SNAP25; the transgenic protein acted beyond the conﬁnes of its host cell.
Using intracellular dyes, no important cytotoxic effectswere observed from reagent treatment alone,which excluded the possibility ofmembrane
ruptures, though noticeably, intracellular acidic organelles were redistributed towards the plasma membrane. This drastic, yet frequently
unobserved, change in protein permeability and endosomal trafﬁcking following reagent treatment highlights important concerns for all studies
using transient transfection. J. Cell. Biochem.115: 2047–2054, 2014. ©2014TheAuthors. JournalofCellularBiochemistryPublishedbyWileyPeriodicals, Inc.
This is an open access article under the terms of the Creative Commons Attribution 3.0 License, which permits use, distribution and reproduction in anymedium, provided the
original work is properly cited.
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The delivery of exogenous proteins into cells and tissues hasbeen invaluable for biological sciences and medicine [Gao and
Huang, 1995]. These modulations of intracellular parameters
brought forth by the addition of heterologous genes, following the
advent of cloning methodologies, greatly accelerated discovery
platforms in all biochemical ﬁelds [Geisse and Voedisch, 2012].
Transfection, a non-viral mediated genetic transfer, relies on a
number of different yet consequently similar approaches. Reagents
such as polycationic liposomes and polymers form cargo bound
liposomes known as lipoplexes or polyplexes respectively [Tros de
Ilarduya et al., 2010] that bind to extracellular membranes to be
internalized. Other chemical reagents such as calcium phosphate or
cyclodextrins and physical treatments such as electroporation
and sonoporation can also promote the intracellular delivery of
the genetic material [Graham and van der Eb, 1973; Neumann
et al., 1982; Song et al., 2007; Menuel et al., 2008]. Alternatively,
biolistic delivery mechanisms can directly ﬁre DNA-coated nano-
particles into cells and tissues for localized exogene expression
[O’Brien and Lummis, 2011; Arsenault and O’Brien, 2013].
The most commonly used approaches however, utilize polyca-
tionic lipids and polymers [Kim and Eberwine, 2010]; a wide range of
these different formulations are commercially available [Caracciolo
and Amenitsch, 2012]. Taking advantage of the overall anionic
charge on the extracellular surface of the plasma membranes, these
lipoplexes bind onto, and get internalized into the cells through
endocytosis. Following a yet not fully understood mechanism, the
DNA cargo gets released where it can subsequently be transcribed in
the nucleus [Tarahovsky et al., 2004; Caracciolo and Amenitsch,
2012; Liu and Zhang, 2012; Lonez et al., 2012]. Current advances are
aimed towards improving the yields of transfections and lowering
the cellular toxicity [Liu and Zhang, 2012; Lonez et al., 2012;
Nguyen and Szoka, 2012]. These formulations inherently interact
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with and modulate the plasma membrane0s ability to internalize the
complexed cargos [Caracciolo and Amenitsch, 2012; Lonez
et al., 2012]. These same types of reagents have also been exploited
to deliver protein cargos themselves into cells [Zelphati et al., 2001;
Oba and Tanaka, 2012]. Yet there is limited data on the ability of the
translated exogenous protein, if released from the primary host cell,
to subsequently penetrate into reagent treated but non-transfected
cells.
In order to determine transfection yield, researchers often rely on
ﬂuorescently tagged chimeras, immunostaining, and radioligand
binding (or radio-labeling) [Bajohrs et al., 2004; Ramos-Vara, 2005;
Arsenault et al., 2010a,b]. These methods, nevertheless having their
own innate advantages, might not have the necessary sensitivity to
detect very low levels of the exogenous protein.
Here, we show that a SNAP25 protease [Jahn et al., 2003;
Montal, 2010; Davletov et al., 2012], the Botulinum neurotoxin
serotype1A(BoNT/A)holoenzyme (LcA), lacking its innatecell surface
binding and translocation domains, tagged with enhanced green
ﬂuorescence protein (EGFP), once expressed inside an initial host cell
can escape, at undetectable concentrations, and subsequently be
internalized intoasecondary, reagent treated,yetnon-transfectedcell.
Since these proteases, which are potent exocytotic inhibitors, have
previously been shown permeable into cells treated with transfection
reagents, such as Fugene HD, Lipofectamine 2000, and Lipofectamine
LTX [Kuo et al., 2010; Arsenault et al., 2014], it is surprising that their
ability tomigrate fromcell-to-cell, following transient expression, has
never been addressed. In fact, there is very little investigation as to
whether any protein can re-enter secondary cells once transiently
expressed even though theymight have been shown amenable to lipid
mediated delivery themselves. These observations become extremely
problematic in transfection studies where highly potent proteins are
investigated (e.g., transcription factors, enzymes, and toxins)
[Montagne et al., 2012; Arsenault et al., 2013], in cases where cells
are compared to their neighbors based on visual conﬁrmation of the
exogenous protein, when the transfected cells are separated and
independently analyzed, when transfected proteins are used as a
readout to follow trafﬁcking processes.
To investigate whether these observation were restricted to the
BoNT/A Lc we also veriﬁed the BoNT/E holoenzyme; the results were
identical. We also determined that the Ricin holoenzyme shows an
over 200-fold increase in efﬁcacy in cells treated with the same
transfection reagent; this untargeted enzyme can thus also
penetrate transfected cells indiscriminately [Lord and Spooner,
2011; Arsenault et al., 2014]. FITC-conjugated peptides could be
detected within organelles of transfected but not untransfected cells.
These results reveal an altered membrane homeostasis and binding
capacity as well as altered endosomal trafﬁcking following
lipofection. These results should be strongly considered for proper
conclusive interpretations of any transfection study.
MATERIALS AND METHODS
Full materials and method has been included as supplementary
information. Brieﬂy, cell culturing, immunocytochemistry, cyto-
toxicity assays, western immunoblotting, ﬂow cytometry, and
confocal microscopy was performed as described elsewhere
[Arsenault et al., 2014]. Transfection of Neuro2A cells was performed
as manufacturer recommends using pDNA vectors described else-
where [Bajohrs et al., 2004]. Peptides and proteins used in this study
were described previously [Arsenault et al., 2013; Arsenault
et al., 2014]. Annexin V-FITC and Ricin A chain were obtained
from Sigma-Aldrich (Dorset, UK).
RESULTS
DISCREPANCIES IN TRANSFECTION YIELDS
Following transient transfection, various methods can be used to
determine the relative exogene expression yields. As can be seen in
Figure 1, various traditional methods to quantify the expression of
the transient exogene EGFP-LcA expression using Lipofectamine
LTX into Neuro2A cells are presented. Using ﬂow cytometry cells
were gated by their forward and side-scatter (size and complexity) to
select only morphologically normal cells. These gated cells were then
quantiﬁed proportional to their EGFP ﬂuorescent intensity (Fig. 1A).
We also veriﬁed EGFP expression using confocal microscopy
(Fig. 1B). Cells expressing the EGFP-LcA present a ﬂuorescence
that is generally localized around the cytosolic face of the plasma
membrane. Western immunoblotting was also used to determine the
total enzymatic effect within the entire sample. Total SNAP25 was
immunoblotted using the SMI81 antibody revealing both the intact
and the BoNT/A cleaved fragment. As can be seen in Figure 1C, the
cleavage of the 9 C-terminal residues (SNAP25D9) leads to the
appearance of a lower MWband. Surprisingly, this readout shows an
improbably high transfection percentage. Figure 1D shows these
quantiﬁcations where both ﬂow cytometry and confocal microscopy
correlates well despite the extra-ordinarily high enzymatic efﬁcacy.
ALTERNATIVE MODES OF PROTEASE ENTRY AND SPREAD OF THE
EXOGENOUS PROTEIN BEYOND THE INITIAL HOST CELL
As was previously shown [Kuo et al., 2010; Arsenault et al., 2014],
transfection reagents can mediate the intracellular entry of BoNT
holoenzymes. Figure 2A shows different conditions where unin-
tended protease penetration can occur. Sheer force, representative of
physical transfection methods, and different transfection reagents
can cause the “transduction“ of the protease.
To determine how intimately the ﬂuorescent signals and protease
activity correlates, we performed immunocytochemistry using a
highly speciﬁc BoNT/A cleaved SNAP25 antibody. As can be seen in
Figure 2B,C, there is no background EGFP nor cleaved SNAP25
signal in both the untreated and mock transfected Neuro2A cells.
However, when EGFP-LcA is expressed within Neuro2A cells we
observe a membrane localized EGFP signal as was previously shown
in Figure 1B and was previously reported elsewhere [Foran
et al., 2003; Bajohrs et al., 2004; Arsenault et al., 2014]. Nevertheless,
we also observe a much more promiscuous anti-cleaved SNAP25
immunoreactivity beyond where lies the EGFP signal. This
observation corroborates the transfection yield discrepancies.
RELEASE OF SNARE PROTEASE FROM HOST CELL AND
TRANSFECTION REAGENT MEDIATED RE-ENTRY
To ascertain whether a much higher percentage of transfection
actually occurs but lies below the threshold of detection or whether
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the EGFP-LcA can escape the conﬁnes of these transfected cells to
cleave SNAP25 in non-transfected cells we sampled the culture
medium at different time points. Figure 3 shows a schematic of this
transfection protocol. Figures 3A and B shows the total enzymatic
readout within undisturbed EGFP-LcA transfected Neuro2A cells;
after 24h a substantial amount of SNAP25 cleavage can already be
observed. This culture medium, which was replaced 6 h after
transfection, was then sampled at different time points and
administered to new Neuro2A cells that were treated with Lipofect-
amine LTX only (Fig. 3C). Since the cells were washed 6 h after
transfection, we removed the remaining free-ﬂoating DNA-lip-
oplexes that could have been carried over to the second generation of
cells. Figure 3D shows that the protease-contaminated culture
medium drawn from the ﬁrst generation of transfected cells as early
as 10h post-wash (16 h post-transfection) can cleave SNAP25 in a
second generation of cells. To avoid seeding the wells with pre-
cleaved SNAP25 we performed western immunoblotting on the
supernatant alone which showed no immunoreactive SNAP25 nor
SNAP25D9 while resuspended EGFP-LcA transfected cells clearly did
(Supplementary Fig. S1). Thus we were not inadvertently transferring
EGFP-LcA transfected cells into new wells. Also, as the 0 h post-wash
seeding does not show any cleaved-SNAP25 in the second generation
of Neuro2A, meaning that the primary cells require synthesis time,
this excludes the possibility of inadvertent DNA-Lipoplex carry over.
To test this further, we centrifuged the sampled medium (Fig. 3C). As
can be seen in Figure 3E, both the soluble (supernatant, SN) and the
suspended (pellet, P) fractions contained the protease. And this also
shows that the penetration of the proteases is dependent on the
presence of the transfection reagent, in this case Lipofectamine LTX.
Thus, once the soluble or suspended proteases are released into the
culturemedium, they can, mediated by the transfection reagent, enter
new untransfected cells where they continue their innate functions.
ABSENCE OF CYTOTOXICITY BUT OBSERVABLE REDISTRIBUTION OF
ACIDIC ORGANELLES
To ascertain whether lipofectamine LTX could adversely affect
Neuro2A cells we performed various survival assays. CCK-8 assay
can quickly and efﬁciently report any cell deaths by monitoring
the colorimetric transition of a tetrazolium salt proportional to
the amount of viable cells. As can be seen in Figure 4A, the
concentration of lipofectamine LTX used (black arrow) did not
display any signiﬁcant loss of viability in Neuro2A cells. Figure 4B
shows three readouts obtained from ﬂow cytometry. The left panel
shows the total proportion of cells bearing a normal morphology as
determined by forward and side scatter. There was no signiﬁcant
disruption in the size and complexity of Neuro2A cells treated with
lipofectamine LTX compared to untreated controls. However, a
moderate elevation was observed in Annexin V-FITC labeling
compared to control (P< 0.05; middle panel) and a slight but non-
signiﬁcant elevation in propidium iodide labeling. If the cytoplasmic
membranes were perforated by the reagent there should have been a
substantial elevation in propidium iodide labeling. These effects
were nevertheless very subtle. As a previous study had shown that
the use of baﬁlomycin A, an endosomal protein pump inhibitor,
could prevent the lipofection mediated entry of Botulinum neuro-
toxins [Kuo et al., 2010] we used lysotracker green to investigate the
distribution of acidic organelles in Neuro2A cells. Firstly, there
seemed to be a larger overall increase in the total ﬂuorescent signal
Fig. 1. Measuring transfection yields. A: Flow cytometry analysis of Mock (gray) and EGFP-LcA (red) transfected Neuro2A cell distribution shown as a histogram of ﬂuorescent
intensity (FL1). B: Confocal microscopy image of EGFP-LcA transfected Neuro2A cells. White bar: 200mm. C: Western immunoblotting of total SNAP25 (SMI81) showing the
enzymatic activity of EGFP-LcA on transfected Neuro2A cells. A total conversion of SNAP25 can be observed. D: Calculated transfection percentage using the above three
interpretation methodologies. There is a strong discrepancy between the ﬂuorescently observed tranfection yields compared to total intracellular enzymatic activity.
JOURNAL OF CELLULAR BIOCHEMISTRY UNEXPECTED TRANSCELLULAR PROTEIN CROSSOVER 2049
or total ﬂuorophore uptake in Neuro2A cells that were treated with
lipofectamine LTX. Furthermore, the distribution of acidic endo-
somal compartments were strongly distributed around the plasma
membrane indicating an active endocytotic/exocytotic process.
Evidently, this active cellular trafﬁcking would undoubtedly
contribute to cargo endocytosis and concomitant exocytosis.
Unfortunately, due to proprietary concerns we were unable to
investigate the individual contribution of the lipofectamine LTX
ingredients.
Whether the enhanced protease internalization observedmight be
a peculiarity of the membrane localization capacity of the BoNT/A
holoenzyme [Fernandez-Salas et al., 2004], we performed the same
tests with the type E protease (EGFP-LcE) a non-membrane bound
SNAP25 protease [Foran et al., 2003]. As can be seen in Figure 5A,
western immunoblotting of total SNAP25 also reveals a near total
SNAP25 cleavage while confocal microscopy and ﬂow cytometry
only detected EGFP-LcA type expression patterns (approximately
40%; data not shown). We also undertook cell survival assays of
Neuro2A cells treated with the ricin holoenzyme, a ribosomal
inactivating protein, in the presence or absence of Lipofectamine
LTX. As can be seen in Figure 5B, there is no detectable cell death 24
and 48 h after this untargeted toxin is incubated with the cells.
However, with cells pre-treated with lipofectamine LTX, a
substantial amount of cell death can be observed at 24 h and,
increasingly so, at 48 h post administration. Also, and as was
previously determined [Arsenault et al., 2014], peptides can be
internalized via transfection reagents. Figure 5C shows Neuro2A
cells treated with or without Lipofectamine LTX and 10mg/ml of
FITC-Syntaxin (201–245) was added to the culture medium for
30min. Following, this incubation cells were washed in PBS and the
medium was replaced. As can be seen, a noticeable amount of
endosomal ﬂuorescence is detectable in the LTX treated Neuro2A
cells but not without pre-treatment. These results show that other
proteins and peptides display a similar ability to be efﬁciently
internalized by Lipofectamine LTX treated cells.
DISCUSSION
Since, a great number of laboratories consistently rely on transient
transfection to tackle important biological and medical questions, it
is crucially important to properly address the ability of the
exogenous protein to act beyond the conﬁnes of its intended
cellular target. Lipofectamine LTX, as well as other transfection
reagents, is currently under proprietary control, which precludes the
analysis of its individual constituents to determine which moiety
facilitates these entries. As was previously determined with BoNT/A
and E, the use of baﬁlomycin A1, an endosomal Hþ pump inhibitor,
could prevent protein transduction, indicating that endocytosis
Fig. 2. Various modes of cellular entry of the type A protease (LcA) and immunoblotting of cleaved SNAP25. A:Western immunoblotting of total SNAP25 (SMI81) for Neuro2A
cells treated with the type A protease under various conditions. Stressors such as sheering force or transfection reagents applied to the cells canmediate the entry of the protease.
B–D: Confocal microscopy of cells immunostained with anti-cleaved SNAP25 antibody (red) and Hoechst stain (blue): (B) Control cells, (C)Mock-transfected cells, and (D) EGFP-
LcA transfected cells (green). The anti-cleaved SNAP25 immunoreactivity can only be seen in cell populations subjected to LcA; this signal also extends beyond the detectable
expression of the EGFP ﬂuorophore.
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followed by translocation rather thanmembrane perforation was the
contributing cause [Kuo et al., 2010]. Our data also supports this
concept as membrane perforation would have affected both
propidium iodide and CCK-8 results, thus the entry mechanisms
are not due to exorbitant membrane perforations or breakage
resulting from necrosis or late apoptosis. Although there was a slight
yet signiﬁcant elevation in the level of Annexin V-FITC binding, this
could also be a false positive as, like the BoNT/A holoenzyme that
localizes on the cytosolic face of the plasma membrane [Bajohrs
et al., 2004; Fernandez-Salas et al., 2004; Wang et al., 2011], this
protein has membrane binding properties which could evidently be
affected by this membrane homeostasis disruption. This would also
correlate with other reports which indicated that Lipofectamine LTX
delivered DNA via the clathrin-mediated endocytosis pathway, a
mechanism traditionally relied upon by Botulinum molecules,
although these transgenes lacked the translocation domain required
for endosomal escape [Wong et al., 2007; Caracciolo et al., 2010].
These observations elicit important questions related to the luminal
to cytosolic translocation of Botulinum neurotoxins.
Another advantage of using BoNTs is that they inhibit exocytosis.
This strongly suggests that the exit pathways are not driven by
SNARE mediated exocytosis. Since BoNT/A and BoNT/E can
signiﬁcantly inhibit exocytosis and both still show almost total
SNAP25 cleavage with transfection rates of less than 50%, it would
be unlikely that exocytosis is the driving force for cellular escape. As
only a few molecules are necessary within the cytosol to
substantially cleave SNAP25, the cells that do express these
heterologous proteins, as observed by ﬂuorescently-tagged readout,
far exceed the requirements to completely cleave SNAP25 within
their host cytosol. That being said, if those cells were to die, their
intracellular contents would be spilled into the culture medium and
thus able to cross over into neighboring untransfected cells. It is also
important to note that both type A and E proteases display no
discernible cytotoxicity in Neuro2A cells [Foran et al., 2003;
Fig. 3. Analyzing the EGFP-LcA transcellular protein crossover by monitoring enzymatic activity. A: Neuro2A cells were transfected with EGFP-LcA; 6 h after transfection the
medium was discarded, cells were washed with PBS, and new complete DMEMwas added. B: Western immunoblotting of SNAP25 showing the total enzymatic efﬁcacy of EGFP-
LcA at different time points (h). C: The new medium was sampled at intervals. This sampled medium, absent of exogenous DNA, was applied to fresh Neuro2A cells treated with
LTX then incubated for 42 h. This medium sampled from previously transfected cells was then centrifuged to separate soluble (supernatant, SN) and suspended (pellet, P)
fractions. These fractions were added onto new Neuro2A cells treated with or without Lipofectamine LTX. D: Western immunoblotting of SNAP25 shows enzymatic efﬁcacy
within the untransfected Neuro2A cells where the sampledmediumwas applied and treated with Lipofectamine LTX. The previously sampledmedium thus contains the EGFP-LcA
protein as detected by enzymatic activity. E:Western immunoblotting of SNAP25 shows that soluble (SN) and suspendedmembrane bound (P) EGFP-LcA are found freely ﬂoating
in the medium and can, mediated by Lipofectamine LTX, enter new Neuro2A cells to cleave intracellular SNAP25.
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Arsenault et al., 2014]. We also cannot exclude reverse translocation
from the cytosolic compartment towards the extra-cellular medium
or into exocytotic vesicle. As some peptides and proteins can enter
cells either by pH dependent transcytosis through the endosomes or
directly through the plasma membrane, little precludes their reverse
transcytosis [Kuo et al., 2010; Madani et al., 2011; Liu and Zhang,
2012; Arsenault et al., 2014] if membrane polarities were disrupted.
The contemporary readout methodologies shown in this study were
not sensitive enough to address the escape issue, yet further research
should be undertaken since all intracellular proteins could display
escape kinetics following reagent treatment. Evidently, mock
conditions are always necessary for any transfection study yet
since they cannot address the effect of the transgene without
transfection reagent, any conclusions taken from the experiment
should consider the implications of transcellular effects.
These results do not necessarily abrogate future chemical
transfection studies, but rather warns that increased amounts of
controls should be undertaken depending on nature of the analysis.
For example, expressing recombinant proteins for puriﬁcation or
targeting all cells for transformation might have little conse-
quences, while however, comparisons of co-treated ﬂuorescent and
non-ﬂuorescent cells might lead to profoundly erroneous inter-
pretations. Furthermore, these observations might also be beneﬁcial
in co-transfection studies where multiple exogenous proteins must
be present within the same cell [Liu et al., 2007]; the exogenous
protein could then diffuse into neighboring cells missing the
DNA coding for one of the cognate components. Miscalculations
might occur when transfection percentage is corroborated to total
functional efﬁcacies. As we observe changes in endosomal
trafﬁcking following Lipofectamine treatment, studies that measure
internalization kinetics following transient transfection should also
be cautious of over interpretation as the transfection reagent itself
might have potentiated and altered the endocytic/exocytotic balance
and membrane homeostasis [Doherty and McMahon, 2008].
When studies rely upon canonical methods to detect the presence
or absence of the exogenous protein, one should always inquire
Fig. 4. Investigating Lipofectamine LTX effects on neuro2A cells. A: CCK-8 assay on Neuro2A cells treated with various doses of Lipofectamine LTX. The consistently used
experimental dose is indicated by an arrow. B: Flow cytometry assays show the percentage of morphologically normal cells (left panel), the amount of Annexin V-FITC labeling
(middle), and propidium iodide labeling (right). C,D: Live imaging of Neuro2A cells treated with or without Lipofectamine LTX and Lysotracker green. C: Normal distribution of
acidic organelles in untreated Neuro2A cells at low magniﬁcation (top) and high (bottom). D: Altered distribution and intensity of acidic organelles following Lipofectamine LTX
treatment shown at low magniﬁcation (top) and high (bottom). Lysotracker green strongly labels the area surrounding the plasma membrane. Low magniﬁcation white bar:
20mm. Higher magniﬁcation white bar: 10mm.
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whether these methods are sufﬁciently sensitive to detect function-
ally relevant intracellular concentrations. Since, the visual recon-
naissance threshold might readily surpass critical intracellular or
intracompartmental concentrations at which the introduced protein
could substantially affect cellular functions, overexpression evi-
dently can aberrantly affect functionality [Cirigliano et al., 2013].
These questionswould always depend upon those proteins0 facility to
exit and enter new cells and organelles as well as their innate
potencies and functions within those locations. One way to
circumvent this issue would be to utilize stable cell lines where,
over a few generations of cellular division, the transfection reagents
can be diluted out or degraded over time.
Although, we have observed that the BoNT/A holoenzyme can re-
enter cells treated with Lipofectamine LTX, we have also shown that
this internalization is not restricted to Botulinum proteases. Since
proteins and peptides can be up-taken by cells, increased research
should be undertaken in order tomore properly deﬁne the interactions
between diverse cell membranes, various proteins, and transfection
reagents especially since the exact mechanisms of internalization or
escape still are not fully understood [Madani et al., 2011; Caracciolo
andAmenitsch, 2012; Lonez et al., 2012].We have studied exogenous
proteases and an N-glycosidase as well as endogenous protein
fragments and they consistently showed an enhanced cellular
internalization following reagent treatment. Evidently, there are
numerous biotechnological and medical implications for such
surprising membrane permeability. The delivery of SNARE protease,
as well as other proteins and peptides, through the use of reagents,
opens new doors for localized pharmaceutical delivery in basic
research, biotechnology, and medicine.
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